Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-01, Vol.378 (4), p.354-369
Hauptverfasser:	Zeuzem, Stefan, Foster, Graham R, Wang, Stanley, Asatryan, Armen, Gane, Edward, Feld, Jordan J, Asselah, Tarik, Bourlière, Marc, Ruane, Peter J, Wedemeyer, Heiner, Pol, Stanislas, Flisiak, Robert, Poordad, Fred, Chuang, Wan-Long, Stedman, Catherine A, Flamm, Steven, Kwo, Paul, Dore, Gregory J, Sepulveda-Arzola, Gladys, Roberts, Stuart K, Soto-Malave, Ruth, Kaita, Kelly, Puoti, Massimo, Vierling, John, Tam, Edward, Vargas, Hugo E, Bruck, Rafi, Fuster, Francisco, Paik, Seung-Woon, Felizarta, Franco, Kort, Jens, Fu, Bo, Liu, Ran, Ng, Teresa I, Pilot-Matias, Tami, Lin, Chih-Wei, Trinh, Roger, Mensa, Federico J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Benzimidazoles - adverse effects Benzimidazoles - therapeutic use Cirrhosis Clinical trials Drug Administration Schedule Drug Combinations Female Genotype Genotype & phenotype Genotypes Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Imidazoles - adverse effects Imidazoles - therapeutic use Infections Interferon Liver cirrhosis Male Medicine Middle Aged Patients Quinoxalines - adverse effects Quinoxalines - therapeutic use RNA, Viral - blood Sofosbuvir - adverse effects Sofosbuvir - therapeutic use Sulfonamides - adverse effects Sulfonamides - therapeutic use Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1702417